Partner at Deerfield Management · Joined 2014
View Live Interactive Profile →Cameron Wheeler, Ph.D., is a Partner on Deerfield's Therapeutics team and joined the firm in 2014. Nuvalent, Inc.'s proxy statement filed 28 April 2026 states that he has held various roles at Deerfield Management Company, L.P. since September 2014, most recently as a Partner in the Biotherapeutics group, and that he served on Nuvalent's board of directors from the company's inception in February 2017, joining its audit committee in June 2025. GSK completed its acquisition of Nuvalent on 15 July 2026, so that board seat is not recorded as current. Before Deerfield he worked for and on behalf of Eleven Biotherapeutics, Inc. as a Director from 2009, was Manager of the Business Development and Operations team at Constellation Pharmaceuticals and a Senior Associate at Third Rock Ventures. He holds a Ph.D. and S.M. in Biological Engineering and an S.B. in Mechanical Engineering from the Massachusetts Institute of Technology.